Related references
Note: Only part of the references are listed.Interferon-γ signal drives differentiation of T-bethi atypical memory B cells into plasma cells following Plasmodium vivax infection
Piyawan Kochayoo et al.
SCIENTIFIC REPORTS (2022)
Enoxacin Up-Regulates MicroRNA Biogenesis and Down-Regulates Cytotoxic CD8 T-Cell Function in Autoimmune Cholangitis
Arata Itoh et al.
HEPATOLOGY (2021)
BAFF signaling in health and disease
Edina Schweighoffer et al.
CURRENT OPINION IN IMMUNOLOGY (2021)
Liver-resident NK cells suppress autoimmune cholangitis and limit the proliferation of CD4+ T cells
Zhi-Bin Zhao et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus (vol 49, pg 725.e1, 2018)
Scott A. Jenks et al.
IMMUNITY (2020)
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Richard Furie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
4 Emerging novel treatments for autoimmune liver diseases
Atsushi Tanaka
HEPATOLOGY RESEARCH (2019)
FCRL5+ Memory B Cells Exhibit Robust Recall Responses
Charles C. Kim et al.
CELL REPORTS (2019)
New therapies for systemic lupus erythematosus - past imperfect, future tense
Grainne Murphy et al.
NATURE REVIEWS RHEUMATOLOGY (2019)
The challenges of primary biliary cholangitis: What is new and what needs to be done
Terziroli Beretta-Piccoli Benedetta et al.
JOURNAL OF AUTOIMMUNITY (2019)
Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
Celine Kaegi et al.
FRONTIERS IN IMMUNOLOGY (2019)
B cell alterations during BAFF inhibition with belimumab in SLE
Daniel Ramskold et al.
EBIOMEDICINE (2019)
Clonal characteristics of paired infiltrating and circulating B lymphocyte repertoire in patients with primary biliary cholangitis
Yan-guo Tan et al.
LIVER INTERNATIONAL (2018)
BAFF and CD4+ T cells are major survival factors for long-lived splenic plasma cells in a B-cell-depletion context
Lan-Huong Thai et al.
BLOOD (2018)
Proteomic analysis reveals distinctive protein profiles involved in CD8+ T cell-mediated murine autoimmune cholangitis
Weici Zhang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
The interplay of type I and type II interferons in murine autoimmune cholangitis as a basis for sex-biased autoimmunity
Heekyong R. Bae et al.
HEPATOLOGY (2018)
Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial
Gemma D. Banham et al.
LANCET (2018)
BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus
Woori Shin et al.
NATURE COMMUNICATIONS (2018)
Evidence for the association between IgG-antimitochondrial antibody and biochemical response to ursodeoxycholic acid treatment in primary biliary cholangitis
Libo Tang et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2017)
Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach
Hani S. Mousa et al.
AUTOIMMUNITY REVIEWS (2016)
B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases
Mathieu Uzzan et al.
DIGESTIVE DISEASES AND SCIENCES (2016)
Chronic Expression of Interferon-Gamma Leads to Murine Autoimmune Cholangitis With a Female Predominance
Heekyong R. Bae et al.
HEPATOLOGY (2016)
Ustekinumab for Patients With Primary Biliary Cholangitis Who Have an Inadequate Response to Ursodeoxycholic Acid: A Proof-of-Concept Study
Gideon M. Hirschfield et al.
HEPATOLOGY (2016)
New Therapies for Primary Biliary Cirrhosis
Annarosa Floreani et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2015)
Advances in pharmacotherapy for primary biliary cirrhosis
Hani S. Mousa et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
Dual B Cell Immunotherapy Is Superior to Individual Anti-CD20 Depletion or BAFF Blockade in Murine Models of Spontaneous or Accelerated Lupus
WeiYu Lin et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Ongoing Activation of Autoantigen-Specific B Cells in Primary Biliary Cirrhosis
Jun Zhang et al.
HEPATOLOGY (2014)
Rituximab Therapy for Primary Sjogren's Syndrome: An Open-Label Clinical Trial and Mechanistic Analysis
E. William St Clair et al.
ARTHRITIS AND RHEUMATISM (2013)
Deletion of Interleukin (IL)-12p35 Induces Liver Fibrosis in Dominant-Negative TGFβ Receptor Type II Mice
Masanobu Tsuda et al.
HEPATOLOGY (2013)
Human Fc Receptor-Like 5 Binds Intact IgG via Mechanisms Distinct from Those of Fc Receptors
Andrea Franco et al.
JOURNAL OF IMMUNOLOGY (2013)
B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies
Maria J. Leandro
ARTHRITIS RESEARCH & THERAPY (2013)
Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus
William Stohl et al.
ARTHRITIS AND RHEUMATISM (2012)
Fc receptor-like 5 promotes B cell proliferation and drives the development of cells displaying switched isotypes
Jessica Dement-Brown et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2012)
B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels
Mark N. Lazarus et al.
RHEUMATOLOGY (2012)
Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity
Y. K. Onno Teng et al.
ARTHRITIS RESEARCH & THERAPY (2012)
B cell-targeted therapy with anti-CD20 monoclonal antibody in a mouse model of Graves' hyperthyroidism
I. Ueki et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2011)
B Cell Depletion Therapy Exacerbates Murine Primary Biliary Cirrhosis
Amy Dhirapong et al.
HEPATOLOGY (2011)
Biliary Apotopes and Anti-Mitochondrial Antibodies Activate Innate Immune Responses in Primary Biliary Cirrhosis
Ana Lleo et al.
HEPATOLOGY (2010)
CD20 deficiency in humans results in impaired T cell-independent antibody responses
Taco W. Kuijpers et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis
Haochu Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation
Y. K. O. Teng et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
B-Cell Depletion with Anti-CD20 Ameliorates Autoimmune Cholangitis but Exacerbates Colitis in Transforming Growth Factor-β Receptor II Dominant Negative Mice
Yuki Moritoki et al.
HEPATOLOGY (2009)
Rituximab Mediates a Strong Elevation of B-Cell-Activating Factor Associated with Increased Pathogen-Specific IgG but Not Autoantibodies in Pemphigus Vulgaris
Angela Nagel et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment
Y. K. Onno Teng et al.
ARTHRITIS AND RHEUMATISM (2007)
Depletion of B cells in murine lupus: Efficacy and resistance
Anupama Ahuja et al.
JOURNAL OF IMMUNOLOGY (2007)
BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome
Jacques-Olivier Pers et al.
ARTHRITIS AND RHEUMATISM (2007)
Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production
Frederic Lavie et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice
Y Hamaguchi et al.
JOURNAL OF IMMUNOLOGY (2005)
Identification of HLA-A2-restricted CD8+ cytotoxic T cell responses in primary biliary cirrhosis:: T cell activation is augmented by immune complexes cross-presented by dendritic cells
H Kita et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Primary biliary cirrhosis: an orchestrated immune response against epithelial cells
ME Gershwin et al.
IMMUNOLOGICAL REVIEWS (2000)
Share Paper
